natgillin/translations-raw huggingface dataset:
Commission Communication entitled ‘Europe 2020 A Strategy for smart, sustainable and inclusive growth’ (the ‘Europe 2020 Strategy’), endorsed by the European Parliament and the Council, emphasises the need to develop favourable conditions for investment in knowledge and innovation so as to achieve smart, sustainable and inclusive growth in the Union.
V Sporočilu Komisije z naslovom „EVROPA 2020 Strategija za pametno, trajnostno in vključujočo rast“ (v nadaljnjem besedilu: strategija Evropa 2020), ki sta jo potrdila Evropski parlament in Svet, je poudarjeno, da je treba razviti ugodne pogoje za naložbe v znanje in inovacije, da bi dosegli pametno, trajnostno in vključujočo rast v Uniji.
Regulation (EU) No 1291/2013 of the European Parliament and of the Council [3] established Horizon 2020 — The Framework Programme for Research and Innovation (2014-2020) (‘Horizon 2020’).
Uredba (EU) št. 1291/2013 Evropskega parlamenta in Sveta [3] je vzpostavila okvirni program za raziskave in inovacije (2014–2020)) (v nadaljnjem besedilu: Obzorje 2020).
Horizon 2020 aims to achieve a greater impact with respect to research and innovation by combining Horizon 2020 and private sector funds in public-private partnerships in key areas where research and innovation can contribute to the Union’s wider competitiveness goals, leverage private investment and help tackle societal challenges.
Cilj Obzorje 2020 je doseči večji učinek na raziskave in inovacije z združevanjem sredstev Obzorje 2020 in sredstev zasebnega sektorja v okviru javno-zasebnih partnerstev na ključnih področjih, na katerih bi lahko raziskave in inovacije prispevale k obsežnejšim ciljem Unije na področju konkurenčnosti, privabile zasebne naložbe in pomagale pri spoprijemanju z družbenimi izzivi.
Those partnerships should be based on a long-term commitment, including a balanced contribution from all partners, be accountable for the achievement of their objectives and be aligned with the Union’s strategic goals relating to research, development and innovation.
Ta partnerstva bi morala temeljiti na dolgoročni zavezi, ki vključuje uravnotežen prispevek vseh partnerjev, nositi bi morala odgovornost za dosego svojih ciljev in biti usklajena s strateškimi cilji Unije na področju raziskav, razvoja in inovacij.
The governance and functioning of those partnerships should be open, transparent, effective and efficient and give the opportunity to a wide range of stakeholders active in their specific areas to participate.
Upravljanje in delovanje teh partnerstev bi moralo biti odprto, pregledno, učinkovito in uspešno, sodelovanje v njih pa bi morali omogočiti širokemu krogu zainteresiranih strani, dejavnih na posameznih področjih.
In accordance with Regulation (EU) No 1291/2013, Union involvement in those partnerships may take the form of financial contributions to joint undertakings established on the basis of Article 187 of the Treaty on the Functioning of the European Union under Decision No 1982/2006/EC.
V skladu z Uredbo (EU) št. 1291/2013 lahko Unija v navedenih partnerstvih sodeluje s finančnimi prispevki za skupna podjetja, ustanovljena na podlagi člena 187 Pogodbe o delovanju Evropske unije v skladu s Sklepom št. 1982/2006/ES.
In accordance with Regulation (EU) No 1291/2013 and Council Decision 2013/743/EU [4], further support should be provided to joint undertakings established under Decision No 1982/2006/EC under the conditions specified in Decision 2013/743/EU.
V skladu z Uredbo (EU) št. 1291/2013 in Sklepom Sveta 2013/743/EU [4] bi bilo treba skupnim podjetjem, ustanovljenim na podlagi Sklepa št. 1982/2006/ES, zagotoviti dodatno podporo pod pogoji iz Sklepa 2013/743/EU.
The Joint Undertaking for the implementation of the Joint Technology Initiative on Innovative Medicines (‘IMI Joint undertaking’) set up by Council Regulation (EC) No 73/2008 [5] has demonstrated the effective mobilisation of resources by bringing together several partners from the pharmaceutical industry, academia, small and medium-sized enterprises (‘SMEs’), patient organisations and regulators.
Skupno podjetje za izvedbo skupne tehnološke pobude za inovativna zdravila (v nadaljnjem besedilu: Skupno podjetje IMI), ustanovljeno z Uredbo Sveta (ES) št. 73/2008 [5], je dokazalo, da je učinkovito mobiliziralo vire z združevanjem več partnerjev iz farmacevtske industrije, akademskih krogov, malih in srednjih podjetij (v nadaljnjem besedilu: MSP), organizacij pacientov in regulatornih organov.
The IMI Joint Undertaking has also stepped up cooperation between stakeholders in the health research and innovation field by allowing access to other partners’ expertise and increasing the collaboration between the pharmaceutical industry and other stakeholders in the Union by developing comprehensive research agendas and horizontal policy coordination.
Skupno podjetje IMI je okrepilo tudi sodelovanje med zainteresiranimi stranmi na področju raziskav in inovacij v zdravstvu z zagotavljanjem dostopa do strokovnega znanja drugih partnerjev ter s pospešitvijo sodelovanja med farmacevtsko industrijo in drugimi zainteresiranimi stranmi v Uniji prek razvoja celovitih raziskovalnih programov in horizontalnega usklajevanja politik.
No other European or national programme has enabled cross-company collaboration within the pharmaceutical sector on the scale that has been achieved by the Joint Technology Initiative on Innovative Medicines.
Noben drug evropski ali nacionalni program ni omogočil tako obsežnega sodelovanja med podjetji v farmacevtski panogi kot skupna tehnološka pobuda za inovativna zdravila.
The interim evaluation of the IMI Joint Undertaking underlined that it enables mutual learning and provides an opportunity to improve the reciprocal understanding of the stakeholders, thus benefiting all parties, and that it has significantly contributed to the transition towards an open innovation model in biopharmaceutical research.
Vmesna ocena Skupnega podjetja IMI je pokazala, da podjetje omogoča vzajemno učenje in zagotavlja možnosti za izboljšanje vzajemnega razumevanja med zainteresiranimi stranmi, kar koristi vsem stranem in je pomembno prispevalo k prehodu na model odprtih inovacij v biofarmacevtskih raziskavah.
Research related to the future of medicine should be undertaken in areas where combination of societal, public health and biomedical industry competitiveness goals requires the pooling of resources and fostering collaboration between the public and private sectors, with the involvement of SMEs.
Raziskave, povezane s prihodnostjo medicine, bi se morale izvajati na področjih, na katerih so zaradi povezanosti družbenih in javnozdravstvenih ciljev konkurenčnosti ter ciljev konkurenčnosti biomedicinske industrije potrebni združevanje virov in spodbujanje sodelovanja med javnim in zasebnim sektorjem ter vključenost MSP.
The initiative should consequently seek to involve a broader range of partners, including mid-caps, from different sectors, such as biomedical imaging, medical information technology, diagnostic and animal health industries.
Obsežnejše sodelovanje bi pomagalo pospešiti razvoj novih pristopov in tehnologij za preprečevanje, diagnosticiranje in zdravljenje bolezni, ki imajo velik vpliv na javno zdravje.
A wider participation would help to advance the development of new approaches and technologies for the prevention, diagnosis and treatment of diseases with high impact on public health.
Novo skupno podjetje bi moralo biti ustanovljeno za izvajanje skupne tehnološke pobude za inovativna zdravila (v nadaljnjem besedilu: Skupno podjetje IMI2) ter bi moralo nadomestiti in naslediti Skupno podjetje IMI.
A new joint undertaking should be established for the implementation of the Joint Technology Initiative on Innovative Medicines (‘IMI2 Joint Undertaking’) and should replace and succeed the IMI Joint Undertaking.
Skupno podjetje IMI2 bi si moralo prizadevati za okrepitev zmogljivosti manjših subjektov, kot so raziskovalne organizacije, univerze ter MSP, za sodelovanje v odprtih inovacijskih modelih ter spodbujanje sodelovanja MSP pri svojih dejavnostih v skladu z zastavljenimi cilji.
The IMI2 Joint Undertaking should seek to foster the capacity of smaller actors such as research organisations, universities and SMEs for participating in open innovation models and to promote the involvement of SMEs in its activities, in line with its objectives.
Pri nadaljevanju te pobude bi bilo treba upoštevati tudi izkušnje, pridobljene pri delovanju Skupnega podjetja IMI, vključno z rezultati njegove vmesne ocene in priporočili zainteresiranih strani, ter jo izvajati z uporabo struktur in pravil, ki bolj ustrezajo namenu, da bi se povečala učinkovitost in zagotovila poenostavitev na operativni ravni.
The continuation of this initiative should also take into account the experience acquired from the operations of the IMI Joint Undertaking including the results of its interim evaluation and stakeholders’ recommendations and should be implemented using a structure and rules that are more fit for its purpose in order to enhance efficiency and ensure simplification at operational level.
Zato bi moralo Skupno podjetje IMI2 sprejeti finančna pravila, specifična za njegove potrebe, v skladu s členom 209 Uredbe (EU, Euratom) št. 966/2012 Evropskega parlamenta in Sveta [6].
To that effect, the IMI2 Joint Undertaking should adopt financial rules specific to its needs in accordance with Article 209 of Regulation (EU, Euratom) No 966/2012 of the European Parliament and of the Council [6].
Člani Skupnega podjetja IMI2 razen Unije so se strinjali, da se raziskovalne dejavnosti na področju Skupnega podjetja IMI2 izvajajo v okviru strukture, ki je bolje prilagojena javno-zasebnemu partnerstvu.
The Members other than the Union of the IMI2 Joint Undertaking have agreed to pursue the research activities in the area of activities of the IMI2 Joint Undertaking within a structure better adapted to the nature of a public-private partnership.
Primerno je, da člani Skupnega podjetja IMI2 razen Unije iz zasebnega sektorja s potrditvenim dopisom sprejmejo Statut, določen v Prilogi k tej uredbi.
It is appropriate that the Members other than the Union of the IMI2 Joint Undertaking accept the Statutes contained in the Annex to this Regulation by means of a letter of endorsement.
Zaradi nadaljnjega razvoja ciljev Skupnega podjetja IMI2 bi moralo biti članstvo odprto tudi za druge pravne subjekte.
As a means to further develop the IMI2 Joint Undertaking’s objectives, membership should also be open to other legal entities.
Poleg tega bi bilo treba pravnim subjektom, ki želijo podpirati cilje Skupnega podjetja IMI2 na svojih specifičnih področjih raziskav, ponuditi možnost, da postanejo pridruženi partnerji Skupnega podjetja IMI2.
Moreover, legal entities interested in supporting the IMI2 Joint Undertaking’s objectives in their specific areas of research should be offered the possibility to become Associated Partners of the IMI2 Joint Undertaking.
Moralo bi biti omogočeno, da lahko katera koli upravičena institucija postane udeleženka ali koordinatorka v izbranem projektu.
It should be possible for any eligible institution to become a participant or a coordinator in the selected projects.
Skupno podjetje IMI2 bi moralo za dosego svojih ciljev zagotavljati finančno podporo udeležencem, predvsem z dodeljevanjem nepovratnih sredstev na podlagi javnih in konkurenčnih razpisov za zbiranje predlogov.
To achieve its objectives, the IMI2 Joint Undertaking should provide financial support to participants mainly in the form of grants following open and competitive calls for proposals.
Udeleženci bi morali biti v celoti seznanjeni z veljavnimi pravnimi in postopkovnimi pogoji, tudi pogoji, določenimi na podlagi člena 1(3) Uredbe (EU) št. 1290/2013 Evropskega parlamenta in Sveta [7], zlasti glede upravičenosti do financiranja ter izkoriščanja in razširjanja rezultatov.
The participants should be fully informed about applicable legal and procedural conditions, including those laid down on the basis of Article 1(3) of Regulation (EU) No 1290/2013 of the European Parliament and of the Council [7], especially regarding eligibility for funding and the exploitation and dissemination of results.
Ti pogoji bi morali biti skladni in smiselni ter bi morali zagotavljati enako in pravično obravnavo udeležencev glede lastništva rezultatov, doseženih v okviru projektov Skupnega podjetja IMI2, in dostopa do njih.
Those conditions should be consistent and reasonable and should ensure equitable and fair treatment of participants regarding ownership of and access to the results generated within the IMI2 Joint Undertaking’s projects.
Prispevki zasebnih članov razen Unije bi se morali nanašati na upravne stroške Skupnega podjetja IMI2, skupaj s prispevki pridruženih partnerjev na njihovih specifičnih področjih raziskav pa na sofinanciranje, potrebno za izvajanje raziskovalnih in inovativnih ukrepov, ki jih podpira Skupno podjetje IMI2.
The contributions from the Members other than the Union should relate to the administrative costs of the IMI2 Joint Undertaking and, together with the contributions from the Associated Partners for their specific area of research, to the co-financing required to carry out research and innovation actions supported by the IMI2 Joint Undertaking.
Sodelovanje v posrednih ukrepih, ki jih financira Skupno podjetje IMI2, bi moralo biti skladno z Uredbo (EU) št. 1290/2013.
Participation in indirect actions funded by the IMI2 Joint Undertaking should comply with Regulation (EU) No 1290/2013.
Skupno podjetje IMI2 bi moralo z ustreznimi ukrepi, ki jih sprejme Komisija, zagotavljati tudi dosledno uporabo teh pravil.
The IMI2 Joint Undertaking should, moreover, ensure consistent application of those rules based on relevant measures adopted by the Commission.
Skupno podjetje IMI2 bi moralo za zagotovitev odprtosti in preglednosti ter spodbujanje sodelovanja uporabljati tudi elektronska sredstva, ki jih upravlja Komisija.
The IMI2 Joint Undertaking should also use electronic means managed by the Commission to ensure openness and transparency and facilitate participation.
Zato bi bilo treba razpise za zbiranje predlogov Skupnega podjetja IMI2 objaviti tudi na enotnem portalu za udeležence ter prek drugih elektronskih sredstev razširjanja v okviru Obzorje 2020, ki jih upravlja Komisija.
Therefore, the calls for proposals launched by the IMI2 Joint Undertaking should also be published on the single portal for participants as well as through other Horizon 2020 electronic means of dissemination managed by the Commission.
Poleg tega bi moralo Skupno podjetje IMI2 za vključitev v elektronske sisteme za poročanje in razširjanje v okviru Obzorje 2020, ki jih upravlja Komisija, predložiti ustrezne podatke, med drugim o predlogih, prosilcih, dodeljenih nepovratnih sredstvih in udeležencih, v ustrezni obliki in časovnem okviru, ki ustrezata obveznostim Komisije glede poročanja.
Moreover, relevant data on, inter alia, proposals, applicants, grants and participants should be made available by the IMI2 Joint Undertaking for inclusion in Horizon 2020 reporting and dissemination electronic systems managed by the Commission, in an appropriate format and with the periodicity corresponding to the Commission’s reporting obligations.
Finančni prispevek Unije bi bilo treba upravljati v skladu z načelom dobrega finančnega poslovodenja in ustreznimi pravili o posrednem upravljanju iz Uredbe (EU, Euratom) št. 966/2012 ter Delegirane uredbe Komisije (EU) št. 1268/2012 [8].
The Union financial contribution should be managed in accordance with the principle of sound financial management and with the relevant rules on indirect management set out in Regulation (EU, Euratom) No 966/2012 and Commission Delegated Regulation (EU) No 1268/2012 [8].
Zaradi poenostavitve bi bilo treba za vse strani zmanjšati upravna bremena.
For the purpose of simplification, the administrative burden should be reduced for all parties.
Izogibati bi se bilo treba dvojnim revizijam ter nesorazmernemu dokumentiranju in poročanju.
Double audits and disproportionate amounts of documentation and reporting should be avoided.
Revizije prejemnikov sredstev Unije na podlagi te uredbe bi bilo treba izvajati v skladu z Uredbo (EU) št. 1291/2013.
Audits of recipients of Union funds under this Regulation should be carried out in compliance with Regulation (EU) No 1291/2013.
Finančne interese Unije in drugih članov Skupnega podjetja IMI2 bi bilo treba v celotnem ciklusu odhodkov zaščititi s sorazmernimi ukrepi, med katerimi so preprečevanje, odkrivanje in preiskovanje nepravilnosti, povračilo izgubljenih, napačno plačanih ali nepravilno porabljenih sredstev ter po potrebi upravne in finančne kazni v skladu z Uredbo (EU, Euratom) št. 966/2012.
The financial interests of the Union and of the other Members of the IMI2 Joint Undertaking should be protected through proportionate measures throughout the expenditure cycle, including the prevention, detection and investigation of irregularities, the recovery of funds lost, wrongly paid or incorrectly used and, where appropriate, administrative and financial penalties in accordance with Regulation (EU, Euratom) No 966/2012.
Notranji revizor Komisije bi moral imeti v Skupnem podjetju IMI2 enaka pooblastila, kot jih ima v zvezi s Komisijo.
The Commission’s internal auditor should exercise the same powers over the IMI2 Joint Undertaking as those exercised in respect of the Commission.
Glede na posebno naravo in trenutni status skupnih podjetij ter za zagotovitev nadaljnjega izvajanja sedmega okvirnega programa bi bilo treba za skupna podjetja še naprej uporabljati ločen postopek razrešnice.
In view of the specific nature and the current status of the joint undertakings, and to ensure continuity with the Seventh Framework Programme, the joint undertakings should continue to be subject to a separate discharge.
Z odstopanjem od členov 60(7) in 209 Uredbe (EU, Euratom) št. 966/2012 bi moral razrešnico za izvrševanje proračuna Skupnega podjetja IMI2 zato podeliti Evropski parlament na priporočilo Sveta.
By way of derogation from Articles 60(7) and 209 of Regulation (EU, Euratom) No 966/2012, discharge for the implementation of the budget of the IMI2 Joint Undertaking should therefore be given by the European Parliament on the recommendation of the Council.
Zahteve glede poročanja iz člena 60(5) Uredbe (EU, Euratom) št. 966/2012 se torej ne bi smele uporabljati za finančni prispevek Unije za Skupno podjetje IMI2, temveč bi jih bilo treba čim bolj uskladiti z zahtevami, predvidenimi za organe iz člena 208 Uredbe (EU, Euratom) št. 966/2012.
Hence, the reporting requirements set out in Article 60(5) of Regulation (EU, Euratom) No 966/2012 should not apply to the Union financial contribution to the IMI2 Joint Undertaking but they should be aligned to the extent possible to the ones foreseen for bodies under Article 208 of Regulation (EU, Euratom) No 966/2012.
Revizijo računovodskih izkazov ter zakonitosti in pravilnosti osnovnih poslov bi moralo opraviti Računsko sodišče.
The auditing of accounts and of the legality and regularity of the underlying transactions should be undertaken by the Court of Auditors.
Skupno podjetje IMI2 bi moralo delovati na odprt in pregleden način s pravočasnim zagotavljanjem vseh zadevnih informacij svojim ustreznim organom in s promocijo svojih dejavnosti, vključno z dejavnostmi obveščanja in razširjanja informacij v širši javnosti.
The IMI2 Joint Undertaking should operate in an open and transparent way providing all relevant information in a timely manner to its appropriate bodies as well as promoting its activities, including information and dissemination activities to the wider public.
Poslovnik organov Skupnega podjetja IMI2 bi bilo treba objaviti.
The rules of procedure of the bodies of the IMI2 Joint Undertaking should be made publicly available.
V okviru Obzorje 2020 je bil ustanovljen znanstveni odbor za zdravje kot v znanost usmerjena platforma zainteresiranih strani, ki pripravlja znanstvene prispevke, zagotavlja celovito, znanstveno usmerjeno analizo ovir in priložnosti za raziskave in inovacije, povezanih z družbenim izzivom v okviru Obzorje 2020, v zvezi z zdravjem, demografskimi spremembami in blaginjo, prispeva k opredelitvi z njim povezanih prednostnih nalog na področju raziskav in inovacij ter spodbuja udeležbo znanstvene skupnosti iz vse Unije.
The Scientific Panel for Health was set up by Horizon 2020 as a science-led stakeholder platform, in order to elaborate scientific input, to provide a coherent scientific focused analysis of research and innovation bottlenecks and opportunities related to the Horizon 2020 societal challenge on health, demographic change and well-being, to contribute to the definition of its research and innovation priorities and to encourage Union-wide scientific participation.
Ob dejavnem sodelovanju zainteresiranih strani prispeva h krepitvi zmogljivosti ter spodbujanju izmenjave znanja in tesnejšega sodelovanja v vsej Uniji na tem področju.
Through active cooperation with stakeholders, it helps to build capabilities and to foster knowledge-sharing and stronger collaboration across the Union in that field.
Skupno podjetje IMI2 bi zato moralo po potrebi sodelovati in izmenjevati informacije z znanstvenim odborom za zdravje.
The IMI2 Joint Undertaking should, therefore, collaborate and exchange information with the Scientific Panel for Health, where appropriate.
Obzorje 2020 bi moral prispevati k odpravi razkoraka med raziskavami in inovacijami v Uniji, saj spodbuja sinergije z evropskimi strukturnimi in investicijskimi skladi.
Horizon 2020 should contribute to the closing of the research and innovation divide within the Union by promoting synergies with the European Structural and Investment Funds (ESIF).
Zato bi si moralo Skupno podjetje IMI2 prizadevati za vzpostavitev tesnih povezav z omenjenimi skladi, ki lahko prispevajo zlasti h krepitvi lokalnih, regionalnih ter nacionalnih raziskovalnih in inovacijskih zmogljivosti na področju delovanja Skupnega podjetja IMI2 in podprejo prizadevanja za pametno specializacijo.
The IMI Joint Undertaking was set up for a period up to 31 December 2017.
Zaradi pravne varnosti in jasnosti bi bilo zato treba razveljaviti Uredbo (ES) št. 73/2008 in določiti prehodne določbe.
The IMI2 Joint Undertaking should provide continued support to the Innovative Medicines research programme by implementing the remaining actions initiated under Regulation (EC) No 73/2008 in accordance with that Regulation.
V skladu s splošnim ciljem Obzorje 2020 glede dodatne poenostavitve in doseganja večje skladnosti bi bilo treba v vseh razpisih za zbiranje predlogov v okviru Skupnega podjetja IMI2 upoštevati trajanje Obzorje 2020.
The transition from the IMI Joint Undertaking to the IMI2 Joint Undertaking should be aligned and synchronised with the transition from the Seventh Framework programme to Horizon 2020 to ensure optimal use of the funding available for research.
Ker ciljev te uredbe, in sicer ustanovitve Skupnega podjetja IMI 2 z namenom krepitve industrijskih raziskav in inovacij v Uniji, države članice ne morejo zadovoljivo doseči, temveč se zaradi preprečevanja podvajanja, ohranjanja kritične mase in zagotavljanja optimalne porabe javnih sredstev lažje dosežejo na ravni Unije, lahko Unija sprejme ukrepe v skladu z načelom subsidiarnosti iz člena 5 Pogodbe o Evropski uniji.
In the interest of legal certainty and clarity, Regulation (EC) No 73/2008 should therefore be repealed and transitional provisions should be set out.
V skladu z načelom sorazmernosti iz navedenega člena ta uredba ne presega tistega, kar je potrebno za doseganje navedenih ciljev –
Given the aim of Horizon 2020 to achieve greater simplification and coherence, all calls for proposals by the IMI2 Joint Undertaking should take into account the duration of Horizon 2020.
SPREJEL NASLEDNJO UREDBO: